new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors




Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
06/30/16Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
06/23/16Vegf antagonist formulations
06/23/16Human antibodies to influenza hemagglutinin
06/23/16Stem cells for modeling type 2 diabetes
06/23/16Methods and compositions for targeted genetic modification through single-step multiple targeting
06/09/16Non-human animals having a humanized cluster of differentiation 274 gene
06/09/16Non-human animals having a humanized cluster of differentiation 47 gene
06/02/16Mirna-regulated differentiation-dependent self-deleting cassette
06/02/16Methods for treating dry eye disease by administering an il-6r antagonist
06/02/16Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
05/26/16Methods and formulations for treating vascular eye diseases
05/26/16Anti-erbb3 antibodies and uses thereof
05/26/16Methods and compositions for targeted genetic modification using paired guide rnas
05/19/16Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
05/19/16Methods for treating high cardiovascular risk patients with hypercholesterolemia
05/12/16Modified chimeric polypeptides with improved pharmacokinetic properties
05/05/16Methods of using il-1 antagonists to treat alzheimer's disease
05/05/16Anti-pdgfr-beta antibodies and uses thereof
04/28/16Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
04/28/16Nuclease-mediated dna assembly
04/28/16Novel cho integration sites and uses thereof
04/21/16Genetic modification of rats
04/21/16Methods and compositions for generating or maintaining pluripotent cells
04/14/16Non-human animals with modified immunoglobulin heavy chain sequences
04/14/16Use of a vegf antagonist to treat angiogenic eye disorders
04/14/16Process for reducing subvisible particles in a pharmaceutical formulation
04/14/16Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
04/07/16Enhanced expression and stability regions
03/31/16Fucosylation-deficient cells
03/24/16Chimeric antigen receptors
03/24/16Anti-il-25 antibodies and uses thereof
03/17/16Treatment of fibrodysplasia ossificans progressiva
03/17/16Anti-glucagon antibodies and uses thereof
03/03/16Human lambda light chain mice
03/03/16Human lambda light chain mice
03/03/16Methods and compositions for the targeted modification of a genome
02/25/16Non-human animals having a humanized signal-regulatory protein gene
02/25/16Humanized il-7 rodents
02/25/16Efficient selectivity of recombinant proteins
02/18/16Angiopoietin-based interventions for treating cerebral malaria
02/18/16Methods and compositions for targeted genetic modifications and methods of use
02/04/16Biologically active molecules, conjugates thereof, and therapeutic uses
02/04/16Stabilized formulations containing anti-pcsk9 antibodies
02/04/16Isolating cells expressing secreted proteins
01/28/16Genetically modified t cell receptor mice
01/28/16Purification platform for bispecific antibodies
01/28/16Human antibodies to grem1
01/28/16Human antibodies to nav1.7
01/21/16Stabilized formulations containing anti-ngf antibodies
01/14/16Humanized dipeptidyl peptidase iv (dpp4) animals
01/07/16Anti-asic1 antibodies and uses thereof
01/07/16Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
12/31/15Human antibodies to human delta like ligand 4
12/31/15Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
12/31/15Nuclease-mediated dna assembly
12/31/15Methods and compositions for modifying a targeted locus
12/31/15Methods and compositions for targeted genetic modifications and methods of use
12/24/15Non-human animals having a humanized programmed cell death 1 gene
12/24/15Humanized il-15 animals
12/10/15Hybrid light chain mice
12/10/15Humanized dipeptidyl peptidase iv (dpp4) animals
12/10/15Production cell line enhancers
12/03/15Genetically modified major histocompatibility complex mice
11/26/15Human antibodies to middle east respiratory syndrome - coronavirus spike protein
11/26/15Anti-egfr antibodies and uses thereof
11/26/15Human antibodies to the glucagon receptor
11/19/15Genetically modified non-human animals expressing human epo
11/19/15Vegf-a121 assay
11/19/15Vegf-a121 assay
11/12/15Humanized il-4 and il-4ra animals
11/12/15Humanized il-4 and il-4ra animals
11/12/15Human lambda light chain mice
11/05/15Common light chain mouse
11/05/15Humanized c5 and c3 animals
11/05/15Low affinity fcgr deficient mice
10/22/15Human antibodies to fel d1 and methods of use thereof
10/22/15Production cell line enhancers
10/22/15Production cell line enhancers
10/15/15Non-human animals that make single domain binding proteins
10/15/15Mirna-regulated differentiation-dependent self-deleting cassette
10/08/15Non-human animals having humanized fc-gamma receptors
10/08/15Anti-pcsk9 antibodies with ph-dependent binding characteristics
10/01/15Humanized il-6 and il-6 receptor
09/24/15Anti-prokineticin receptor (prokr) antibodies and uses thereof
09/24/15Methods and antibody compositions for tumor treatment
09/24/15Vl antigen binding proteins exhibiting distinct binding characteristics
09/17/15Anti-egfrviii antibodies and uses thereof
09/10/15Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
09/10/15Aplnr modulators and uses thereof
09/03/15Genetically modified major histocompatibility complex animals
09/03/15Methods for treating or preventing asthma by administering an il-4r antagonist
09/03/15Methods for treating skin infection by administering an il-4r antagonist
09/03/15Hybrid light chain mice
09/03/15Hybrid light chain mice
08/20/15Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
08/20/15Human antibodies to human delta like ligand 4
07/30/15Genetically modified non-human animals and methods of use thereof
07/30/15Adam6 mice
07/23/15Adam6 mice
07/23/15Human antibodies to pd-1
07/23/15Human antibodies to pd-l1
07/23/15Mutivalent antigen-binding proteins
07/16/15Mice that make heavy chain antibodies
07/16/15Mice that make heavy chain antibodies
07/16/15Mice that make heavy chain antibodies
07/16/15Mice that make heavy chain antibodies
07/16/15Mice that make heavy chain antibodies
07/16/15Mice that make heavy chain antibodies
07/16/15Anti-angptl3 antibodies and uses thereof
07/16/15Anti-tie2 antibodies and uses thereof
07/09/15Human antibodies to human delta like ligand 4
06/25/15Human lambda light chain mice
06/25/15Human lambda light chain mice
06/25/15Fusion polypeptides capable of activating receptors
06/25/15Production cell line enhancers
06/25/15Human lambda light chain mice
06/18/15Devices and methods for facilitating treatment of electrospray columns
06/18/15Antikine antibodies that bind to multiple cc chemokines
06/11/15Isolating cells expressing secreted proteins
06/04/15High affinity human antibodies to human angiopoietin-2
06/04/15Dosing regimens for use with pcsk9 inhibitors
05/28/15Methods for treating cancer by administering an anti-ang-2 antibody
05/21/15Use of a pcsk9 inhibitor to treat hyperlipidemia
05/21/15Non-human animals having a humanized b-cell activating factor gene
05/21/15Non-human animals having a humanized a proliferation-inducing ligand gene
05/21/15Non-human animals having a humanized b-cell activating factor gene
05/21/15Non-human animals having a humanized a proliferation-inducing ligand gene
04/30/15Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
04/23/15High resolution allele identification
04/23/15Human antibodies to gfr alpha 3 and methods of use thereof
04/16/15Syringe pistons, systems and methods
04/16/15Humanized il-15 animals
04/09/15Promoter-regulated differentiation-dependent self-deleting cassette
04/09/15Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
03/26/15Non-human animals having a humanized signal-regulatory protein gene
03/26/15Non-human animals having a humanized signal-regulatory protein gene
03/26/15Human lambda light chain mice
03/19/15Vegf antagonist formulations
03/19/15Humanized il-7 rodents
03/05/15Method of treating cancer with dll4 antagonist and chemotherapeutic agent
03/05/15Production of fertile xy female animals from xy es cells
02/26/15Anti-prlr antibodies and uses thereof
02/26/15Anti-prlr antibodies and uses thereof
02/26/15Methods for making fully human bispecific antibodies using a common light chain
02/12/15Humanized m-csf mice
02/12/15Lincrna-deficient non-human animals
02/05/15Anti-activin a antibodies and uses thereof
02/05/15Genetically modified major histocompatibility complex mice
01/22/15Humanized fcgammar mice
01/15/15Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
01/15/15Methods for treating nasal polyposis by administering an il-4r antagonist
01/15/15Non-human animals with modified immunoglobulin heavy chain sequences
01/08/15Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
01/08/15Humanized il-6 and il-6 receptor
01/08/15Humanized il-6 and il-6 receptor
12/04/14Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
12/04/14Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
12/04/14Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
11/06/14Methods and compositions for generating a mouse
10/30/14Methods of inhibiting tumor growth by antagonizing il-6 receptor
10/23/14Inducible eukaryotic expression system
09/25/14Mice that make heavy chain antibodies
09/18/14Il-33 antagonists and uses thereof
09/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
09/18/14Anti-il-33 antibodies and uses thereof
09/18/14High affinity human antibodies to human il-4 receptor
09/18/14Serum-free cell culture medium
09/18/14Apelin fusion proteins and uses thereof
09/18/14Rodents with conditional acvr1 mutant alleles
09/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
09/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
09/11/14Methods of treating autoimmune diseases with dll4 antagonists
09/11/14High affinity antibodies to human il-6 receptor
09/04/14Readily isolated bispecific antibodies with native immunoglobulin format
08/28/14Antibodies comprising chimeric constant domains
08/28/14Humanized t cell co-receptor mice
08/28/14Genetically modified major histocompatibility complex mice
08/28/14Non-human animals with modified immunoglobulin heavy chain sequences
08/07/14Method of treating osteoarthritis with an antibody to ngf
07/31/14Adam6 mice
07/17/14Systems and devices for sample handling
07/17/14Promoter-regulated differentiation-dependent self-deleting cassette
07/10/14Anti-pdgfr-beta antibodies and uses thereof
07/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
07/03/14Mirna-regulated differentiation-dependent self-deleting cassette
06/26/14Compositions and methods for modifying cells
06/26/14High affinity human antibodies to human protease-activated receptor 2
06/05/14Humanized fc gamma r mice
06/05/14Methods of modifying genes in eukaryotic cells
06/05/14Low affinity fcgr deficient mice
05/22/14System and methods for use in dispensing biopharmaceutical materials
05/15/14Methods of treating ovarian cancer with dll4 antagonists
05/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
05/15/14Recombinant cell surface capture proteins
05/15/14Hybrid light chain mice
05/08/14Mice that make vl binding proteins
05/08/14Mice that make vl binding proteins
05/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
04/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
04/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
03/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
03/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
03/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
03/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
03/13/14Isolating cells expressing secreted proteins
03/13/14Isolating cells expressing secreted proteins
03/13/14Methods of modifying eukaryotic cells
03/13/14Parental cell lines for making cassette-free f1 progeny
02/27/14Human antibodies to gfr alpha 3 and methods of use thereof
02/27/14Anti-asic1 antibodies and uses thereof
02/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
02/06/14Methods of modifying eukaryotic cells
01/30/14Methods of modifying eukaryotic cells
01/30/14Methods of modifying eukaryotic cells
01/23/14Methods of modifying eukaryotic cells
01/16/14Humanized light chain mice
01/16/14Methods of modifying eukaryotic cells
01/16/14Methods of modifying eukaryotic cells
01/16/14Isolating cells expressing secreted proteins
01/16/14Methods of modifying eukaryotic cells
01/16/14Methods for modifying eukaryotic cells
01/16/14Methods of modifying eukaryotic cells
01/16/14Methods of modifying eukaryotic cells
01/16/14Methods of modifying eukaryotic cells
01/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
01/09/14Methods of modifying eukaryotic cells
12/26/13Human antibodies to the glucagon receptor
12/19/13Humanized il-7 rodents
12/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
12/05/13Stabilized formulations containing anti-dll4 antibodies
12/05/13Purified antibody composition
12/05/13Production cell line enhancers
12/05/13Human lambda light chain mice
12/05/13Restricted immunoglobulin heavy chain mice
12/05/13Human lambda light chain mice
11/21/13Nuclease-mediated targeting with large targeting vectors
11/21/13Promoter-regulated differentiation-dependent self-deleting cassette
11/21/13Promoter-regulated differentiation-dependent self-deleting cassette
11/07/13Human antibodies to fel d1 and methods of use thereof
10/24/13Fusion polypeptides capable of activating receptors
10/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
10/10/13Human antibodies to human angiopoietin-like protein 4
10/03/13Anti-hla-b*27 antibodies and uses thereof
10/03/13Fusion polypeptides capable of activating receptors
10/03/13Vegf antagonist formulations
09/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
09/26/13Adam6 mice
09/19/13Multispecific antigen-binding molecules and uses thereof
09/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###